Arcadia Biosciences, Inc. (RKDA) Stock Price & Analysis
Arcadia Biosciences, Inc. (RKDA) fell 0.52% to USD 0.92 as of June 10, 2026 at 05:09 UTC, according to Nexqual real-time market data.
RKDA last closed at USD 0.92; the session ranged USD 0.83–0.92 on volume of 67,172 shares. Market capitalization is $1.89M, with a 52-week range of USD 0.8–6.71 (NCM). Source: Nexqual, June 10, 2026 at 05:09 UTC.
Key Statistics (as of June 10, 2026 at 05:09 UTC)
| Price | USD 0.92 |
|---|---|
| Change | ▼ 0.52% (down) |
| Previous Close | USD 0.92 |
| Open | USD 0.89 |
| Day Range | USD 0.83 – 0.92 |
| 52-Week Range | USD 0.8 – 6.71 |
| Volume | 67,172 shares |
| Market Cap | $1.89M |
| Exchange | NCM |
Technical Analysis (RKDA)
Nexqual's technical model rates RKDA "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:09 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.73 (neutral) |
| vs SMA50 | Below (USD 1.12) |
| MACD | -0.04 (negative) |
Analyst Ratings (RKDA)
Wall Street analysts rate RKDA "None", per Nexqual as of June 10, 2026 at 05:09 UTC.
| Consensus Rating | None |
|---|
Earnings (RKDA)
| Next Earnings Date | 2026-03-19 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD 0.62 vs est -0.54 ▲ beat |
| 2025-06-30 | USD -3.26 vs est -0.79 ▼ miss |
| 2025-03-31 | USD 1.9 vs est -0.98 ▲ beat |
| 2024-12-31 | USD -2.99 vs est -0.89 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:09 UTC.
Financials & Fundamentals (RKDA)
| Total Revenue | $4.76M |
|---|---|
| Revenue Growth (YoY) | -8.30% |
| Gross Margin | +34.32% |
| Operating Margin | -70.82% |
| Profit Margin | -195.94% |
| ROE | -158.15% |
| Current Ratio | 3.79 |
| Total Cash | $3.72M |
| Total Debt | $0 |
| Free Cash Flow | $872,375 |
Source: Nexqual, June 10, 2026 at 05:09 UTC.
Financial Health Score (RKDA)
Nexqual rates Arcadia Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:09 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $4M cash, no debt |
| Cash Flow | Strong — FCF $872K, 17% margin |
| Efficiency | Critical — ROE -158%, ROA -32.8% |
Ownership (RKDA)
| Insider Ownership | +0.55% |
|---|---|
| Institutional Ownership | +16.99% |
| Shares Outstanding | 2.06M |
| Float | 1.77M |
| Short % of Float | +20.02% |
Source: Nexqual, June 10, 2026 at 05:09 UTC.
Leadership (RKDA)
Arcadia Biosciences, Inc. is led by Thomas J. Schaefer C.F.A. (age 49), CEO, Interim CFO, Principal Accounting Officer, President, Corporate Secretary & Director, per Nexqual as of June 10, 2026 at 05:09 UTC.
| CEO, Interim CFO, Principal Accounting Officer, President, Corporate Secretary & Director | Thomas J. Schaefer C.F.A. (age 49) |
|---|
Major Backers & Investors (RKDA)
Notable institutional backers of Arcadia Biosciences, Inc. include Armistice Capital, LLC, Sabby Management, LLC, Fidelity, according to Nexqual as of June 10, 2026 at 05:09 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 7.75% |
| Sabby Management, LLC | 5.57% |
| Fidelity | 1.52% |
| Susquehanna International Group, LLP | 0.61% |
| Tower Research Capital LLC (TRC) | 0.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.54% |
| Vanguard Group | 1.15% |
| State Street | 0.59% |
Source: Nexqual, June 10, 2026 at 05:09 UTC.
From Arcadia Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Partnerships
- On December 24, 2025, the Company received a notice from Roosevelt indicating that it was terminating the Exchange Agreement with immediate effect pursuant to the Termination Provision, as the closing of the Exchange had not occurred by the Termination Date specified in the Amendment.
- On March 28, 2025, Arcadia entered into an agreement with Bioceres Crop Solutions Corp. ("BIOX") pursuant to which BIOX agreed to transfer to the Company all rights and materials relating to certain soy traits that were included in licenses granted by the Company to BIOX in the November 2020 sale of Verdeca.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BPTH | Bio-Path Holdings, Inc. | USD 0.04 | ▼ 10% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| TENX | Tenax Therapeutics, Inc. | USD 10.73 | ▲ 0% |
| CFOR | OpGen, Inc. | USD 2 | ▲ 300% |
| XBIO | Xenetic Biosciences, Inc. | USD 3.08 | ▼ 0.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:09 UTC. This page is informational and not investment advice.